Business Wire

Digital Therapeutics Alliance and Healthware Group Partner to Build European Coalition to Scale Access to Digital Therapeutics

Share

The Digital Therapeutics Alliance (DTA) and Healthware Group today announced a partnership to form a coalition convening thought leaders, policymakers, and professional and trade associations from across the European region to discuss and develop harmonised pathways for the recognition and scalability of digital therapeutics (DTx) at the local, national, and regional levels.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614005168/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Digital Therapeutics Alliance and Healthware Group Partner to Build European Coalition to Scale Access to Digital Therapeutics (Photo: Business Wire)

Developing this pan-European coalition will be a catalysing factor for the successful scaling of DTx therapies across countries. The first in-person meeting of the coalition will take place at Frontiers Health Global Conference this coming October in Milan, Italy. The coalition will focus on co-creating a vision for the future by analysing existing frameworks and infrastructure, sharing learnings, and developing recommendations to build an environment which ensures safe and effective DTx therapies can be accessible to patients regardless of where they live.

The partnership between Healthware and DTA is part of the Alliance’s Resource Partner program, a best-in-class network of leading experts in the rapidly evolving DTx industry who collaborate with DTA members to develop resources to advance digital therapeutics to transform global healthcare. Through this relationship, Healthware will also support DTA’s Europe Policy Task Group, which is focused on understanding and informing key aspects of the European policy landscape, including Health Technology Assessment frameworks, national funding, clinician engagement, and patient access and reimbursement pathways.

This announcement follows a longstanding collaboration between the two organisations, which began with DTA’s European launch at the Frontiers Health Global Conference in 2017. The development of a pan-European coalition will deepen DTA’s presence in the region and further its mission to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics into healthcare through education, advocacy, and cross-industry collaboration.

Healthware brings over a decade of experience and advocacy of digital health/digital therapeutics and an even longer history of developing digitally focused solutions for life sciences, payors and medical device companies. Healthware has also developed a corporate investment fund to support and invest in digital health companies and nurtures a vast digital health network and expertise. In the area of digital therapeutics specifically, Healthware Group supports both the research and development of DTx products as well as the go to market, access, system integration and adoption strategies in partnership with pharmaceutical companies, digital health and DTx companies and all ecosystem stakeholders.

“We have been partnering with Healthware since the inception of DTA and are thrilled to have their knowledge and expertise on board,” shared Megan Coder, DTA Chief Policy Officer. “As we jointly develop this coalition, our aim is to enable full scale access to digital therapeutics throughout Europe to transform critical aspects of patient care.”

Roberto Ascione , CEO of Healthware Group says, “My team at Healthware has been helping shape the digital health landscape in Europe for many years, through our work with Frontiers Health and in direct support of our clients. We are excited to deepen our partnership with DTA to help shape the European policy landscape and ensure DTx companies can scale. We are huge advocates for the positive impact digital therapeutics can have on patients and believe that these solutions can help fill care gaps, augment care delivery and most importantly support patients in novel ways.”

Healthware and DTA look forward to building this coalition together and are seeking the active participation of key stakeholders across the region. Further announcements about the coalition and how to get involved will be rolling out soon.

* * *

Healthware Group
Healthware Group is a global health innovation and technology leader providing transformational advisory and technology services for commercial, medical, and R&D operations of life-sciences and digital health companies, combined with design and development of digital medicines and digital therapeutics products.
Proprietary software platforms, specialised media and educational assets as well as a corporate venturing arm, ensure accelerated product development, close integration within the innovation ecosystem, continuous pipeline development and superior market access capabilities.
Founded in Italy in 1997 by CEO and digital health pioneer Roberto Ascione, Healthware Group encompasses several vertical brands, including flagship commercial and medical communications agency Healthware International, media consultancy Healthware Engage, innovation consultancy Healthware Labs, and creative motion lab & virtual hybrid events specialist SWM and the digital therapeutics R&D partner and product portfolio organisation, Healthware Therapeutics.
It also operates Healthware Ventures, the corporate investment arm that supports digital health start-ups with a focus on digital therapeutics and telehealth and is the co-host of the global leading digital health conference Frontiers Health.
Healthware has a team of 200+ professionals with main offices in Salerno, London, New York, Milan, Helsinki and, together with its joint venture partner Intouch Group, has a combined reach of 1,500+ people in over 15 offices in Europe, the US, and Asia.
Thanks to the Argon Global Healthcare acquisition, the group also runs the Healthware Global Network, one of the largest international networks of independent healthcare agencies covering 25 Countries worldwide.
Healthware Group is privately owned and backed by FITEC, a leading European VC fund focusing on technology.
For more information, please visit healthwaregroup.com and follow us on LinkedIn and Twitter.

Digital Therapeutics Alliance

The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Healthware Group
Antonietta Pannella, Marketing & Communications Director
Mobile: +39 349 0648276 - Email: antonietta.pannella@healthwaregroup.com

Digital Therapeutics Alliance
Hannah Fairman, Director of Communications
Email: hfairman@dtxalliance.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas: Strong Start to the Year; 2024 Outlook Confirmed25.4.2024 10:20:00 EEST | Press release

Q1 2024 Key figures1 › Revenue of EUR 1,439.5 million in the first quarter of 2024, up 2.5% year-on-year and up 8.0% organically › Strong organic growth from Industry +16.3%, Certification +13.7%, Marine & Offshore +13.6%, compared to the first quarter of 2023; growth of +6.1% for Consumer Products Services, +3.6% for Buildings & Infrastructure and +3.2% for Agri-food & Commodities › The scope effect was a positive 0.1%, reflecting bolt-on acquisitions offset by a small disposal › The currency impact was negative by 5.6% mainly due to the depreciation of some emerging countries’ currencies against the euro Q1 2024 Highlights › New strategy LEAP | 28, announced on March 20, 2024, to deliver a step change in growth and performance, built around three pillars: Focused Portfolio, Performance-led execution and Evolved People model › Strong growth in every region (Americas, Middle East, Africa, Asia-Pacific and Europe), outperforming many underlying markets › Growth momentum maintained for s

New CPS Protection Platform: TXOne Networks Presents SageOne in Hannover25.4.2024 10:04:00 EEST | Press release

TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man Number One. This central management console provides an overview of the CPS attack surface of the OT environment. All three TXOne product lines can be centrally controlled, namely Stellar for endpoint protection, Element for security inspection and Edge for network defense. The platform offers integrated OT security across the entire lifecycle of the objects to be protected and enables reliable detection and response to threats. SageOne essentially covers three main pillars: CPS Attack Surface Management: Visibility is a cornerstone for cybersecurity. A clear view of the overall security posture helps identify security focal points in an OT environment. SageOne focuses on operational security by honing in on assets and illuminating the securi

Infobip becomes an Oracle Independent Software Vendor partner25.4.2024 10:00:00 EEST | Press release

Infobip, a global cloud communications platform and a member of Oracle PartnerNetwork (OPN), today announced it has enhanced its relationship with Oracle, becoming an Independent Software Vendor (ISV) with access to Oracle Integration Cloud. Businesses using any Oracle solution can access Infobip’s omnichannel platform through Oracle Cloud Marketplace (OCM). They can quickly orchestrate powerful interactions, help increase customer satisfaction, boost sales, and improve campaign performance. Oracle Cloud Marketplace is a one-stop shop for Oracle customers seeking trusted business applications and services offering unique solutions, including ones that extend Oracle Fusion Cloud Applications. Infobip’s communication channels will enable businesses to deliver conversational experiences across many sectors including banking and financial services, retail and ecommerce, and hospitality and leisure. Through Infobip’s collaboration, Oracle users will gain customer insights, enabling them to

Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 06:00:00 EEST | Press release

AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 23:01:00 EEST | Press release

Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin is a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune system and the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye